Navkiran Kaur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Navkiran Kaur has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Shivani Sharda
Amity Institute of Biotechnology, Amity University, Uttar Pradesh, Noida, 201313, India
7 shared publications - Anupama Avasthi
Amity Institute of Biotechnology, Amity University Uttar Pradesh
6 shared publications - Sudeep Bose
Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India
4 shared publications Meghavi Kathpalia
Amity University , India
3 shared publicationsAlka Sehgal
2 shared publications- Amarish Kumar Sharma
Department of Biotechnology, Parul Institute of Technology, Parul University, Vadodara, India
1 shared publication
Latest Publications
- Open Access
- 27 March 2026
- Published by Springer Nature in BMC Immunology
- Vol. 27  (1)
In silico design and immunoinformatics evaluation of a multi-epitope vaccine targeting SEPT9 for gastrointestinal adenocarcinomas
Gastrointestinal adenocarcinomas are a major cause of mortality globally, underpinning the desire for new approaches to immunotherapeutic strategies. SEPT9 is clinically validated as an FDA-approved colorectal cancer biomarker, suggesting its potential as a candidate antigen for vaccine development. An immunoinformatic pipeline created a multi-epitope chimera vaccination using strict standards of high antigenicity, non-allergenicity, non-toxicity, and worldwide population coverage. Five epitopes (three MHC-I and two MHC-II) were ranked from SEPT9. Selected epitopes were concatenated with suitable linkers for MHC-I and MHC-II, connected to a human β-defensin adjuvant. The construct composed of 134 amino acids was built using the trRosetta algorithm, refined using the GalaxyRefine2.0 algorithm, and validate via PROCHECK, ERRAT and ProSA. Immune response prediction was conducted by performing docking studies against TLR2 and TLR4 (via ClusPro software), and performing C-ImmSim immune simulations. The designed construct demonstrated predicted favorable physicochemical properties (solubility: 0.89), safety, and immunogenicity potential in silico. Docking ΔG values (TLR2: –17.7 kcal/mol; TLR4: –23.9 kcal/mol) and immune simulation data indicated theoretical potential to trigger innate and adaptive immunity. The SEPT9-based multi-epitope vaccine construct demonstrated promising predicted immunogenic and structural properties in silico. However, these findings are computational and hypothesis-generating; experimental validation is required to assess immunogenicity, safety, and therapeutic efficacy in biological systems.
- 27 March 2026
- Published by Springer Nature in BMC Immunology
- Vol. 27  (1)
Open AccessIn silico design and immunoinformatics evaluation of a multi-epitope vaccine targeting SEPT9 for gastrointestinal adenocarcinomas
Gastrointestinal adenocarcinomas are a major cause of mortality globally, underpinning the desire for new approaches to immunotherapeutic strategies. SEPT9 is clinically validated as an FDA-approved colorectal cancer biomarker, suggesting its potential as a candidate antigen for vaccine development. An immunoinformatic pipeline created a multi-epitope chimera vaccination using strict standards of high antigenicity, non-allergenicity, non-toxicity, and worldwide population coverage. Five epitopes (three MHC-I and two MHC-II) were ranked from SEPT9. Selected epitopes were concatenated with suitable linkers for MHC-I and MHC-II, connected to a human β-defensin adjuvant. The construct composed of 134 amino acids was built using the trRosetta algorithm, refined using the GalaxyRefine2.0 algorithm, and validate via PROCHECK, ERRAT and ProSA. Immune response prediction was conducted by performing docking studies against TLR2 and TLR4 (via ClusPro software), and performing C-ImmSim immune simulations. The designed construct demonstrated predicted favorable physicochemical properties (solubility: 0.89), safety, and immunogenicity potential in silico. Docking ΔG values (TLR2: –17.7 kcal/mol; TLR4: –23.9 kcal/mol) and immune simulation data indicated theoretical potential to trigger innate and adaptive immunity. The SEPT9-based multi-epitope vaccine construct demonstrated promising predicted immunogenic and structural properties in silico. However, these findings are computational and hypothesis-generating; experimental validation is required to assess immunogenicity, safety, and therapeutic efficacy in biological systems.
- Top Cited PapersOpen Access
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of Mid-life Health
- Vol. 16  (3) , 247-256
Estrogen and Metabolism: Navigating Hormonal Transitions from Perimenopause to Postmenopause
Estrogen is a key hormone that influences metabolism, health, and overall well-being throughout a woman’s life. Its levels fluctuate across different reproductive stages: perimenopause, menopause, and postmenopause – each bringing unique physiological changes. During perimenopause, estrogen helps regulate insulin production, glucose metabolism, and fat distribution. However, as levels become unstable in this phase, women may experience increased insulin resistance, shifts in fat storage, and a greater risk of metabolic disorders such as diabetes. Given its widespread effects, proactive lifestyle interventions are essential. A balanced diet rich in phytoestrogens, regular physical activity, and maintaining a healthy body weight can help manage hormonal shifts. Advancing research in molecular endocrinology and personalized medicine offers the potential for targeted strategies that deepen our understanding of estrogen’s tissue-specific effects. By personalizing interventions to individual hormonal transitions, we can improve women’s health outcomes and quality of life.
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of Mid-life Health
- Vol. 16  (3) , 247-256
Top Cited PapersOpen AccessEstrogen and Metabolism: Navigating Hormonal Transitions from Perimenopause to Postmenopause
Estrogen is a key hormone that influences metabolism, health, and overall well-being throughout a woman’s life. Its levels fluctuate across different reproductive stages: perimenopause, menopause, and postmenopause – each bringing unique physiological changes. During perimenopause, estrogen helps regulate insulin production, glucose metabolism, and fat distribution. However, as levels become unstable in this phase, women may experience increased insulin resistance, shifts in fat storage, and a greater risk of metabolic disorders such as diabetes. Given its widespread effects, proactive lifestyle interventions are essential. A balanced diet rich in phytoestrogens, regular physical activity, and maintaining a healthy body weight can help manage hormonal shifts. Advancing research in molecular endocrinology and personalized medicine offers the potential for targeted strategies that deepen our understanding of estrogen’s tissue-specific effects. By personalizing interventions to individual hormonal transitions, we can improve women’s health outcomes and quality of life.
- Open Access
- 20 June 2024
- Published by SAGE Publications in Breast Disease
- Vol. 43  (1) , 193-211
Lectins as a promising therapeutic agent for breast cancer: A review
Efficient treatment of cancer has been a subject of research by scientists for many years. Current treatments for cancer, such as radiotherapy, chemotherapy and surgery have been used in traditional combination therapy, but they have major setbacks like non-specificity, non-responsiveness in certain cancer types towards treatment, tumor recurrence, etc. Epidemiological data has shown that breast cancer accounts for 14% of cancer cases occurring in Indian women. In recent years, scientists have started to focus on the use of natural compounds like lectins obtained from various sources to counter the side effects of traditional therapy. Lectins like Sambucus nigra Agglutinin, Maackia amurensis lectin, Okra lectins, Haliclona caerulea lectin, Sclerotium rolfsii lectin, etc., have been discovered to have both diagnostic and therapeutic potential for breast cancer patients. Lectins have been found to have inhibitory effects on various cancer cell activities such as neo-angiogenesis, causing cell cycle arrest at the G1 phase, and inducing apoptosis. The major idea behind the use of lectins in cancer diagnostics and therapeutics is their capability to bind to glycosylated proteins that are expressed on the cell surface. This review focuses on an exploration of the roles of post-translational modification in cancer cells, especially glycosylation, and the potential of lectins in cancer diagnosis and therapeutics.
- 20 June 2024
- Published by SAGE Publications in Breast Disease
- Vol. 43  (1) , 193-211
Open AccessLectins as a promising therapeutic agent for breast cancer: A review
Efficient treatment of cancer has been a subject of research by scientists for many years. Current treatments for cancer, such as radiotherapy, chemotherapy and surgery have been used in traditional combination therapy, but they have major setbacks like non-specificity, non-responsiveness in certain cancer types towards treatment, tumor recurrence, etc. Epidemiological data has shown that breast cancer accounts for 14% of cancer cases occurring in Indian women. In recent years, scientists have started to focus on the use of natural compounds like lectins obtained from various sources to counter the side effects of traditional therapy. Lectins like Sambucus nigra Agglutinin, Maackia amurensis lectin, Okra lectins, Haliclona caerulea lectin, Sclerotium rolfsii lectin, etc., have been discovered to have both diagnostic and therapeutic potential for breast cancer patients. Lectins have been found to have inhibitory effects on various cancer cell activities such as neo-angiogenesis, causing cell cycle arrest at the G1 phase, and inducing apoptosis. The major idea behind the use of lectins in cancer diagnostics and therapeutics is their capability to bind to glycosylated proteins that are expressed on the cell surface. This review focuses on an exploration of the roles of post-translational modification in cancer cells, especially glycosylation, and the potential of lectins in cancer diagnosis and therapeutics.
- 15 May 2024
- Published by Springer Nature
- p. 905-924
Cellular Interactions Network in Cancer: Integrative Disease Models
- 15 May 2024
- Published by Springer Nature
- p. 905-924
Cellular Interactions Network in Cancer: Integrative Disease Models
- 15 May 2024
- Published by Springer Nature
- p. 627-641
Structuring Inflammasome-Epigenome: Phenotypic Axis in Gynecological Cancers
- 15 May 2024
- Published by Springer Nature
- p. 627-641
Structuring Inflammasome-Epigenome: Phenotypic Axis in Gynecological Cancers
- 18 April 2024
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 41  (2) , 79-91
Clinical relevance of glycosylation in triple negative breast cancer: a review
Glycosylation alterations in TNBC have significant implications for tumor behavior, diagnosis, prognosis, and therapeutic strategies. Dysregulated glycosylation affects cell adhesion, signaling, immune recognition, and response to therapy in TNBC. Different types of glycosylation, including N-linked glycosylation, O-linked glycosylation, glycosphingolipid glycosylation, mucin-type glycosylation, and sialylation, play distinct roles in TNBC. The “barcoding” method based on glycosylation sites of the membrane type mannose receptor (MR) shows promise in accurately distinguishing breast cancer subtypes, including TNBC. Alpha-L-fucosidase 1 (FUCA1) and Monocarboxylate transporter 4 (MCT4) have been identified as potential diagnostic and prognostic markers for TNBC. The glycosylation status of PD-L1 impacts the response to immune checkpoint blockade therapy in TNBC. Inhibiting fucosylation of B7H3 enhances immune responses and improves anti-tumor effects. Targeting glycosylated B7H4 and modulating estrogen metabolism through glycosylation-related mechanisms are potential therapeutic strategies for TNBC. Understanding the role of glycosylation in TNBC provides insights into disease mechanisms, diagnosis, and potential therapeutic targets. Further research in this field may lead to personalized treatment approaches and improved outcomes for TNBC patients.
- 18 April 2024
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 41  (2) , 79-91
Clinical relevance of glycosylation in triple negative breast cancer: a review
Glycosylation alterations in TNBC have significant implications for tumor behavior, diagnosis, prognosis, and therapeutic strategies. Dysregulated glycosylation affects cell adhesion, signaling, immune recognition, and response to therapy in TNBC. Different types of glycosylation, including N-linked glycosylation, O-linked glycosylation, glycosphingolipid glycosylation, mucin-type glycosylation, and sialylation, play distinct roles in TNBC. The “barcoding” method based on glycosylation sites of the membrane type mannose receptor (MR) shows promise in accurately distinguishing breast cancer subtypes, including TNBC. Alpha-L-fucosidase 1 (FUCA1) and Monocarboxylate transporter 4 (MCT4) have been identified as potential diagnostic and prognostic markers for TNBC. The glycosylation status of PD-L1 impacts the response to immune checkpoint blockade therapy in TNBC. Inhibiting fucosylation of B7H3 enhances immune responses and improves anti-tumor effects. Targeting glycosylated B7H4 and modulating estrogen metabolism through glycosylation-related mechanisms are potential therapeutic strategies for TNBC. Understanding the role of glycosylation in TNBC provides insights into disease mechanisms, diagnosis, and potential therapeutic targets. Further research in this field may lead to personalized treatment approaches and improved outcomes for TNBC patients.
- 17 August 2023
- Published by Springer Nature
- p. 1-20
Cellular Interactions Network in Cancer: Integrative Disease Models
- 17 August 2023
- Published by Springer Nature
- p. 1-20
Cellular Interactions Network in Cancer: Integrative Disease Models
- 24 July 2023
- Published by Springer Nature
- p. 1-15
Structuring Inflammasome-Epigenome – Phenotypic Axis in Gynecological Cancers
- 24 July 2023
- Published by Springer Nature
- p. 1-15
Structuring Inflammasome-Epigenome – Phenotypic Axis in Gynecological Cancers
- 11 July 2023
- Published by Springer Nature
- p. 1-16
Structuring Inflammasome-Epigenome – Phenotypic Axis in Gynecological Cancers
- 11 July 2023
- Published by Springer Nature
- p. 1-16
Structuring Inflammasome-Epigenome – Phenotypic Axis in Gynecological Cancers
- Open Access
- 15 May 2023
- Published by IP Innovative Publication Pvt Ltd in Indian Journal of Obstetrics and Gynecology Research
- Vol. 10  (2) , 189-195
Nutritional deficiency and MTHFR gene polymorphism in obstetrics
: This study was carried out to determine the association of folic acid deficiency, vitamin B12 deficiency, hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism with obstetrical events linked to folic acid deficiency like neural tube defects (NTD); unexplained abruption placentae (AP), recurrent pregnancy loss (RPL) and preterm labour(PTL).: In the present study 87 pregnant females with past or present history of either neural tube defect (NTD), abruptio placentae, recurrent pregnancy loss (RPL) or preterm labour and 100 pregnant females without any such history were enrolled. Serum levels of folic acid, vitamin B12 and homocysteine in these females were estimated using chemiluminescence and Polyacrylamide gel electrophoresis (PAGE) was used to detect MTHFR gene polymorphism.: No significant association was observed between serum folic acid levels and NTD (p = 0.495), RPL (p = 0.832) or preterm labour (p = 0.724). However, folic acid deficiency had significant association with the occurrence of abruptio placenta (p = 0.001). Serum vit B12 deficiency was found to be a significant risk factor only in patients with RPL. Increased homocysteine revealed significant association with RPL (p= 0.024), abruption placentae (p=0.002) and preterm labour (0.015). No polymorphism in MTHFR gene could be revealed in the above pregnancy complications.: In the present study, deficiency of folic acid was uncommon probably due to its routine supplementation throughout the first trimester. However, preconceptional folic acid supplementation still needs to be emphasized to build up adequate folic acid levels required during embryogenesis. The relationship between vit B12 and RPL needs studies on larger number to establish the association before supplementation is suggested. MTHFR677 gene polymorphism may have remained undetected due to small sample size.
- 15 May 2023
- Published by IP Innovative Publication Pvt Ltd in Indian Journal of Obstetrics and Gynecology Research
- Vol. 10  (2) , 189-195
Open AccessNutritional deficiency and MTHFR gene polymorphism in obstetrics
: This study was carried out to determine the association of folic acid deficiency, vitamin B12 deficiency, hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism with obstetrical events linked to folic acid deficiency like neural tube defects (NTD); unexplained abruption placentae (AP), recurrent pregnancy loss (RPL) and preterm labour(PTL).: In the present study 87 pregnant females with past or present history of either neural tube defect (NTD), abruptio placentae, recurrent pregnancy loss (RPL) or preterm labour and 100 pregnant females without any such history were enrolled. Serum levels of folic acid, vitamin B12 and homocysteine in these females were estimated using chemiluminescence and Polyacrylamide gel electrophoresis (PAGE) was used to detect MTHFR gene polymorphism.: No significant association was observed between serum folic acid levels and NTD (p = 0.495), RPL (p = 0.832) or preterm labour (p = 0.724). However, folic acid deficiency had significant association with the occurrence of abruptio placenta (p = 0.001). Serum vit B12 deficiency was found to be a significant risk factor only in patients with RPL. Increased homocysteine revealed significant association with RPL (p= 0.024), abruption placentae (p=0.002) and preterm labour (0.015). No polymorphism in MTHFR gene could be revealed in the above pregnancy complications.: In the present study, deficiency of folic acid was uncommon probably due to its routine supplementation throughout the first trimester. However, preconceptional folic acid supplementation still needs to be emphasized to build up adequate folic acid levels required during embryogenesis. The relationship between vit B12 and RPL needs studies on larger number to establish the association before supplementation is suggested. MTHFR677 gene polymorphism may have remained undetected due to small sample size.